Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Glucagon like Peptide 1, Glucose Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Efficacy and safety of incretin co agonists: Transformative advances in cardiometabolic healthcare GLP 3 Research Peptide Blend with Cagrilintide Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link